Literature DB >> 19150315

Hypercoagulation in liver disease.

Patrick G Northup1.   

Abstract

The coagulopathy of liver disease is complex and often unpredictable. Despite clear evidence of an increased tendency for bleeding in patients who have cirrhosis, many circumstances also promote local and systemic hypercoagulable states. The consequences of hypercoagulability include the obvious morbidity and mortality of portal vein thrombosis, deep vein thrombosis, and pulmonary embolism, but possibly also include other end-organ syndromes, such as portopulmonary hypertension, hepatorenal syndrome, and spontaneous bacterial peritonitis. A more subtle contribution also could be responsible for progression of early fibrosis to decompensated cirrhosis. Future research is needed to elucidate specific mechanistic pathways that might lead to local hypercoagulation and the clinical interventions that might prevent morbidity and mortality related to hypercoagulation in patients who have cirrhosis.

Entities:  

Mesh:

Year:  2009        PMID: 19150315     DOI: 10.1016/j.cld.2008.09.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  8 in total

1.  Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?

Authors:  Marco Senzolo; Maria Teresa Sartori; Ton Lisman
Journal:  HPB (Oxford)       Date:  2009-09       Impact factor: 3.647

2.  Management of portal vein thrombosis in cirrhotic patients.

Authors:  Lucio Amitrano; Maria Anna Guardascione
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-11-25       Impact factor: 2.576

3.  Viral cirrhosis: an overview of haemostatic alterations and clinical consequences.

Authors:  Francesca Romana Ponziani; Valerio De Stefano; Antonio Gasbarrini
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-30       Impact factor: 2.576

4.  Sonoclot signature analysis in patients with liver disease and its correlation with conventional coagulation studies.

Authors:  Priyanka Saxena; Chhagan Bihari; Archana Rastogi; Savita Agarwal; Lovkesh Anand; Shiv Kumar Sarin
Journal:  Adv Hematol       Date:  2013-12-11

5.  Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.

Authors:  Hsin-Fu Lee; Yi-Hsin Chan; Shang-Hung Chang; Hui-Tzu Tu; Shao-Wei Chen; Yung-Hsin Yeh; Lung-Sheng Wu; Chang-Fu Kuo; Chi-Tai Kuo; Lai-Chu See
Journal:  J Am Heart Assoc       Date:  2019-03-05       Impact factor: 5.501

6.  Platelet activation and hypercoagulability in patients with early primary biliary cholangitis compared with healthy controls.

Authors:  Jiannis Vlachogiannakos; Jiannis Binas; Spyros Siakavellas; Dimitrios S Karagiannakis; Theodoros Voulgaris; George V Papatheodoridis; Spiros D Ladas
Journal:  Ann Gastroenterol       Date:  2021-01-04

7.  Coagulation parameters are associated with the prognosis of immunoglobulin a nephropathy: a retrospective study.

Authors:  Ming Xia; Di Liu; Liang Peng; Yan Li; Haiyang Liu; Lingzhi Wu; Guochun Chen; Yu Liu; Hong Liu
Journal:  BMC Nephrol       Date:  2020-10-27       Impact factor: 2.388

8.  [Monitoring of coagulation by intraoperative thromboelastometry of liver transplantation in a patient using warfarin - case report].

Authors:  José Carlos Rodrigues Nascimento; David Silveira Marinho; Rodrigo Dornfeld Escalante; Bodiyabaduge Emmanuel M Daya Pereira Junior; Cristiane Gurgel Lopes; Rogean Rodrigues Nunes
Journal:  Braz J Anesthesiol       Date:  2018-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.